Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs

被引:157
作者
Villeneuve, L [1 ]
Girard, H [1 ]
Fortier, LC [1 ]
Gagné, JF [1 ]
Guillemette, C [1 ]
机构
[1] Univ Laval, Fac Pharm, CHUL Res Ctr,Oncol & Mol Endocrinol Res Ctr, Canada Chair Pharmacogenom,Pharmacogenom Lab, Quebec City, PQ G1V 4G2, Canada
关键词
D O I
10.1124/jpet.103.054072
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro metabolic studies revealed that along with UDP-glucuronosyltransferase (UGT) 1A1, the hepatic UGT1A9 and the extrahepatic UGT1A7 are involved in the biotransformation of the active and toxic metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38). Variant UGT1A1 and UGT1A7 alleles have been reported but the polymorphic nature of the UGT1A9 gene has not been revealed yet. To further clarify the molecular determinants of irinotecan-induced toxicity, we have identified and characterized the functionality of novel UGT1A9 polymorphisms and determined whether additional missense polymorphisms exist in UGT1A7. Using direct DNA sequencing, four single nucleotide polymorphisms ( SNPs) were identified in the first exons of UGT1A7 and UGT1A9. One of the two amino acid substitutions found in the UGT1A9 gene, UGT1A9*3 ((MT)-T-33), results in a dramatic decrease in SN-38 glucuronide formation, with 3.8% of the activity of the UGT1A9*1 allele. In turn, the glucuronidation of flavopiridol, an anticancer drug biotransformed predominantly by UGT1A9, remains unaffected, indicating a substrate-dependent impact of this variant. UGT1A9*3 is detected only in Caucasians and 4.4% of the population tested was found heterozygous (*1/*3). Two additional UGT1A7 SNPs were found exclusively in African-American subjects and generate five alleles (UGT1A7* 5 to * 9) when combined to the four known SNPs present in UGT1A7* 2, * 3, and * 4. Upon functional analysis with SN-38, five out of nine UGT1A7 allozymes exhibited much lower SN-38 glucuronidation activities compared with UGT1A7* 1, all having in common the mutational changes at codons 115 or 208. Results suggest that these low SN-38 glucuronidating alleles may represent additional molecular determinants of irinotecan-induced toxicity and warrant further investigations.
引用
收藏
页码:117 / 128
页数:12
相关论文
共 41 条
[1]   The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes [J].
Albert, C ;
Vallée, M ;
Beaudry, G ;
Bélanger, A ;
Hum, DW .
ENDOCRINOLOGY, 1999, 140 (07) :3292-3302
[2]   Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients [J].
Ando, M ;
Ando, Y ;
Sekido, Y ;
Ando, M ;
Shimokata, K ;
Hasegawa, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (05) :591-597
[3]  
Ando Y, 2000, CANCER RES, V60, P6921
[4]  
[Anonymous], 2000, ARLEQUIN SOFTWARE PO
[5]   Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus [J].
Ciotti, M ;
Basu, N ;
Brangi, M ;
Owens, IS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (01) :199-202
[6]   UDP glucuronosyltransferase mRNA levels in human liver disease [J].
Congiu, M ;
Mashford, ML ;
Slavin, JL ;
Desmond, PV .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (02) :129-134
[7]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[8]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[9]   Founder TIGR/myocilin mutations for glaucoma in the Quebec population [J].
Faucher, M ;
Anctil, JL ;
Rodrigue, MA ;
Duchesne, A ;
Bergeron, D ;
Blondeau, P ;
Côté, G ;
Dubois, S ;
Bergeron, J ;
Arseneault, R ;
Morissette, J ;
Raymond, V .
HUMAN MOLECULAR GENETICS, 2002, 11 (18) :2077-2090
[10]   Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) [J].
Gagné, JF ;
Montminy, V ;
Belanger, P ;
Journault, K ;
Gaucher, G ;
Guillemette, C .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :608-617